Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 412 of 6351
-
New program aims to stop overdose deaths among women leaving rural jails
Prevention Recruiting nowThis project continues our work with women in the Kentucky Women's Justice Community Overdose Innovation Network Phase II (WJCOIN-II) with the overall aim of reducing overdose risk during the transition from jail to rural communities. WJCOIN-II has potential for significant impac…
Sponsor: Michele Staton • Aim: Prevention
Last updated Aug 30, 2026 00:00 UTC
-
Engineered t cells take on Hard-to-Treat cancers in new trial
Disease control Not yet recruitingThis phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New acid blocker could shield heart patients from stomach bleeding
Disease control Recruiting nowThis study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PC…
Phase 3 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Engineered immune cells take on tough cancers in first human trial
Disease control Recruiting nowThis is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants with R/R SCLC or select NECs
Phase 1 • Sponsor: Moonlight Bio, Inc • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for myeloma patients: drug combo aims to keep cancer at bay
Disease control Recruiting nowThe purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been e…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for angelman syndrome: drug trial targets brain function
Disease control Recruiting nowPurpose of the study is to evaluate the efficacy and safety of intrathecally administered rugonersen in pediatric and adult participants with Angelman syndrome.
Phase 3 • Sponsor: OHB Pediatrics Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New oral drug aims to tame PKU's toxic protein buildup
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, and efficacy of MZE782 in adults with Phenylketonuria (PKU).
Phase 2 • Sponsor: Maze Therapeutics • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Sacred circle, stronger minds: could a cultural practice ease youth stress?
Prevention By invitation onlyThis study, "Talking Circle for Native American Youth Living Well (A Yo Li)" uses a Community Based Participatory Research (CBPR) approach to evaluate Talking Circle effectiveness, partnering with The American Indians in Texas at the Spanish Colonial Missions (AIT-SCM) in Central…
Sponsor: Melessa Kelley • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
New pill could tame lupus flares
Disease control Recruiting nowTo assess the efficacy and safety of TQH3906 in treating systemic lupus erythematosus.
Phase 2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Herbal dripping pills aim to boost exercise capacity in heart failure
Disease control Recruiting nowThis trial will evaluate the efficacy and safety of Qishen Yiqi Dripping Pills in treatment of Chronic Heart Failure with reduced ejection fraction resorted from Coronary Heart Disease (Syndrome of Qi Deficiency with Blood Stasis).
Phase 3 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could training one limb at a time boost heart health better than both?
Disease control Recruiting nowHypertension is associated with autonomic nervous system dysfunction, reduced muscle strength, and impaired functional capacity, all of which contribute to increased cardiovascular risk and decreased quality of life. Resistance training is recommended as a non-pharmacological int…
Sponsor: Hacettepe University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New immunotherapy duo aims to outdo chemo for common lymphoma
Disease control Recruiting nowResearchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL…
Phase 2/3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Massive RSV vaccine study uses real-world data to see if shots prevent severe illness
Disease control OngoingAmong non-pregnant adults observed in Epic Cosmos since August 2023 who are eligible for RSV vaccination, what is the effectiveness of ABRYSVO® (RSVpreF), compared with unvaccinated individuals, in preventing RSV-related and all-cause acute respiratory illness (ARI), lower respir…
Sponsor: Pfizer • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug could boost stroke recovery by calming brain inflammation
Disease control Recruiting nowStroke remains a major global health burden, with acute ischemic stroke (AIS) accounting for more than 65% of all cases. Endovascular thrombectomy (EVT) has been established as a standard treatment for large vessel occlusion (LVO) stroke; however, "futile recanalization" remains …
Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo therapy targets rare lung cancer mutation
Disease control Recruiting nowThis is a prospective, single-arm, Phase II clinical study aimed at evaluating the efficacy and safety of 160mg fimonertinib in combination with definitive radiotherapy for patients with EGFR uncommon driver mutation-positive, Stage III unresectable lung adenocarcinoma. The prima…
Phase 2 • Sponsor: Hunan Cancer Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New obesity drug CagriSema heads to phase 3 trial
Disease control CancelledThis study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of Cagri…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for Late-Stroke patients: drug trial uses advanced imaging to guide treatment
Disease control Recruiting nowThis study aims to address the existing clinical challenges by introducing high-resolution magnetic resonance vessel wall imaging (HR-MRI), an advanced imaging technology, to achieve precise etiological classification in patients with acute ischemic stroke (AIS) beyond the time w…
Phase 3 • Sponsor: Weifang Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Promising PTSD drug moves to Long-Term safety study
Disease control By invitation onlyThis study is evaluating the long-term safety and efficacy of TSND-201 in adults with PTSD. Participants that have completed a double-blind clinical trial with TNSD-201 for PTSD will be invited to participate in this open-label extension trial. Each participant will be able to r…
Phase 3 • Sponsor: Transcend Therapeutics • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for rare leukemia: Four-Drug cocktail targets cancer cells
Disease control Not yet recruitingThe goal of this clinical trial is to learn whether CM336, a BCMA/CD3 bispecific antibody, can improve treatment outcomes when combined with isatuximab, lenalidomide, and bortezomib in adults with newly diagnosed primary plasma cell leukemia (pPCL). The study will also evaluate t…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Old drugs, new hope: could a thalidomide combo free thalassemia patients from transfusions?
Disease control Recruiting nowThe aim of this study is to determine the safety and therapeutic effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on beta thalassemia patients. The main objectives of this study are: * To determine the therapeutic efficacy of HbF inducers (combination th…
Sponsor: Riphah International University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC